To mark the start of Parkinson’s Awareness Month, the Parkinson’s Foundation has kicked off its #FutureofPD Campaign, an initiative to call attention to the progressive neurodegenerative disorder and highlight what can be done to create a better future for the Parkinson’s disease community. “Parkinson’s disease affects nearly…
News
Using Cerevance’s oral CVN424 as an add-on therapy for Parkinson’s motor symptoms led to a significant and meaningful dose-dependent reduction in “off” time — periods when symptoms reappear or worsen — data from a Phase 2 study show. The trial also met its safety objectives, according to a…
Inhibikase expects to begin a Phase 2a study of IkT-148009, its investigational therapy for Parkinson’s disease, in the second quarter of 2022, with dosing of the first patient being subject to clearance by the U.S. Food and Drug Administration (FDA). Last year, the company began dosing IkT-148009…
ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients, new data show. Findings reveal that the vast majority of adverse events (side effects) reported in…
Azilect (rasagiline) as an add-on therapy to Requip (ropinrole) improved sleep, reduced the need for sleep medications, and enhanced quality of life in a small group of people with Parkinson’s disease, a study suggested. These findings support more extensive studies to confirm the sleep-related benefits of Azilect,…
Over-expressing a fly gene called clueless (clu) can lessen mitochondrial defects in fruit fly models of Parkinson’s disease, a new study reveals. The results also showed that CLUH, the human equivalent of the fly clueless gene, has a similar function, which may pave the way toward new treatment approaches for…
A new app called NMS Assist, designed to remotely monitor the non-motor symptoms of Parkinson’s disease, is being developed and tested by researchers at Plymouth University in the U.K. The goal is to offer an application that can track non-motor symptoms — cognitive problems, mood changes, and fatigue,…
In 1817, James Parkinson published “An Essay on the Shaking Palsy,” the first such recognition of a disease that eventually would be known by his name. On April 11, World Parkinson’s Day and the 267th anniversary of Parkinson’s birth, and throughout the month, the Parkinson’s community will raise awareness about…
Vyant Bio and OrganoTherapeutics are teaming up to speed the discovery of new candidates for treating Parkinson’s disease. The collaboration will leverage OrganoTherapeutic’s patient-derived “mini-brains” — midbrain organoids — derived from induced pluripotent stem cells (iPSCs) and Vyant Bio’s expertise in machine learning technology to identify new…
ABBV-951, a continuous infusion formulation of levodopa/carbidopa, brought comparable levels of levodopa into the bloodstream of healthy volunteers as surgically implanted levodopa-carbidopa intestinal gel (LCIG), a Phase 1 study confirmed. Because the delivery of doses can be tailored to a patient’s needs, this alternative form of delivery — a portable…
Recent Posts
- Parkinson’s-like brain abnormalities found in young adults with autism
- Reducing disparities in care, research for women with Parkinson’s disease
- Ethics committee in the Netherlands green lights Parkinson’s clinical trial
- From a long-held wish to a labor of love
- Parkinson’s changed my uncle’s daily life, but his personality remained